Miller ML - Search Results

1

Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies.

Miller ML, Roller EE, Wu X, Leece BA, Goldmacher VS, Chari RV, Ojima I. Miller ML, et al. Bioorg Med Chem Lett. 2004 Aug 2;14(15):4079-82. doi: 10.1016/j.bmcl.2004.05.027. Bioorg Med Chem Lett. 2004. PMID: 15225730

2

Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.

Miller ML, Roller EE, Zhao RY, Leece BA, Ab O, Baloglu E, Goldmacher VS, Chari RV. Miller ML, et al. J Med Chem. 2004 Sep 23;47(20):4802-5. doi: 10.1021/jm049705s. J Med Chem. 2004. PMID: 15369381

3

Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors.

Baloglu E, Miller ML, Roller EE, Cavanagh EE, Leece BA, Goldmacher VS, Chari RV. Baloglu E, et al. Among authors: miller ml. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5885-8. doi: 10.1016/j.bmcl.2004.09.025. Bioorg Med Chem Lett. 2004. PMID: 15501062

4

Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs).

Reid EE, Archer KE, Shizuka M, McShea MA, Maloney EK, Ab O, Lanieri L, Wilhelm A, Ponte JF, Yoder NC, Chari RVJ, Miller ML. Reid EE, et al. Among authors: miller ml. Bioorg Med Chem Lett. 2019 Sep 1;29(17):2455-2458. doi: 10.1016/j.bmcl.2019.07.031. Epub 2019 Jul 19. Bioorg Med Chem Lett. 2019. PMID: 31350125

5

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RV, Lambert JM, Lutz RJ. Kellogg BA, et al. Bioconjug Chem. 2011 Apr 20;22(4):717-27. doi: 10.1021/bc100480a. Epub 2011 Mar 22. Bioconjug Chem. 2011. PMID: 21425776

6

Synthesis of novel C2-C3'N-linked macrocyclic taxoids by means of highly regioselective Heck macrocyclization.

Geng X, Miller ML, Lin S, Ojima I. Geng X, et al. Among authors: miller ml. Org Lett. 2003 Oct 2;5(20):3733-6. doi: 10.1021/ol0354627. Org Lett. 2003. PMID: 14507217

7

Design, synthesis, and biological evaluation of new-generation taxoids.

Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, Zanardi I, Xia S, Horwitz SB, Mallen-St Clair J, Guerriero JL, Bar-Sagi D, Veith JM, Pera P, Bernacki RJ. Ojima I, et al. Among authors: miller ml. J Med Chem. 2008 Jun 12;51(11):3203-21. doi: 10.1021/jm800086e. Epub 2008 May 9. J Med Chem. 2008. PMID: 18465846 Free PMC article.

8

Antibody-drug conjugates: an emerging concept in cancer therapy.

Chari RV, Miller ML, Widdison WC. Chari RV, et al. Among authors: miller ml. Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3796-827. doi: 10.1002/anie.201307628. Epub 2014 Feb 20. Angew Chem Int Ed Engl. 2014. PMID: 24677743 Review.

9

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.

Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV. Miller ML, et al. Mol Cancer Ther. 2016 Aug;15(8):1870-8. doi: 10.1158/1535-7163.MCT-16-0184. Epub 2016 May 23. Mol Cancer Ther. 2016. PMID: 27216304

10

Synthesis and structure-activity relationships of new second-generation taxoids.

Ojima I, Wang T, Miller ML, Lin S, Borella CP, Geng X, Pera P, Bernacki RJ. Ojima I, et al. Among authors: miller ml. Bioorg Med Chem Lett. 1999 Dec 20;9(24):3423-8. doi: 10.1016/s0960-894x(99)00629-0. Bioorg Med Chem Lett. 1999. PMID: 10617084

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

716 results

Search Page

Filters